Phio Pharma To Present PH-762 INTASYL siRNA Skin Cancer Trial Progress And Strategic Outlook At Life Sciences Future Conference Sept. 25-26, 2025
Benzinga Newsdesk 1 year ago
News
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp.
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced that Phio Pharmaceuticals is a presenting company at the Life Sciences Future Conference to be held September 25 - 26, 2025.
Mr. Robert Bitterman, President and CEO of Phio Pharmaceuticals, will deliver an update on its on-going Phase 1b clinical trial for skin cancer. He will also be discussing strategy and anticipated next steps in the PH-762 development program upon completion of the treatment phase of the study. Mr. Bitterman and his management team will also be available for one-on-one meetings throughout the conference September 25 - 26, 2025.